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ABSTRACT
The P2Y14 receptor was initially identified as a G protein-cou-
pled receptor activated by UDP-glucose and other nucleotide
sugars. We have developed several cell lines that stably ex-
press the human P2Y14 receptor, allowing facile examination of
its coupling to native Gi family G proteins and their associated
downstream signaling pathways (J Pharmacol Exp Ther 330:
162–168, 2009). In the current study, we examined P2Y14 re-
ceptor-dependent inhibition of cyclic AMP accumulation in hu-
man embryonic kidney (HEK) 293, C6 glioma, and Chinese
hamster ovary (CHO) cells stably expressing this receptor. Not
only was the human P2Y14 receptor activated by UDP-glucose,
but it also was activated by UDP. The apparent efficacies of
UDP and UDP-glucose were similar, and the EC50 values (74,
33, and 29 nM) for UDP-dependent activation of the P2Y14
receptor in HEK293, CHO, and C6 glioma cells, respectively,
were similar to the EC50 values (323, 132, and 72 nM) observed
for UDP-glucose. UDP and UDP-glucose also stimulated ex-
tracellular signal-regulated kinase (ERK) 1/2 phosphorylation in
P2Y14 receptor-expressing HEK293 cells but not in wild-type
HEK293 cells. A series of analogs of UDP were potent P2Y14
receptor agonists, but the naturally occurring nucleoside
diphosphates, CDP, GDP, and ADP exhibited agonist poten-
cies over 100-fold less than that observed with UDP. Two UDP
analogs were identified that selectively activate the P2Y14 re-
ceptor over the UDP-activated P2Y6 receptor, and these mol-
ecules stimulated phosphorylation of ERK1/2 in differentiated
human HL-60 promyeloleukemia cells, which natively express
the P2Y14 receptor but had no effect in wild-type HL-60 cells,
which do not express the receptor. We conclude that UDP is an
important cognate agonist of the human P2Y14 receptor.
The metabotropic P2Y receptors include a subgroup of five
receptors, the P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors,
that primarily signal through Gq-activated signaling path-
ways and a subgroup of three receptors, the P2Y12, P2Y13,
and P2Y14 receptors, that primarily signal by activating het-
erotrimeric G proteins of the Gi family (Abbracchio et al.,
2006; Burnstock, 2007). The human P2Y1, P2Y11, P2Y12, and
P2Y13 receptors are activated by adenine nucleotides. The
human P2Y4 and P2Y6 receptors are activated by uridine
nucleotides, and the P2Y2 receptor is activated by both ATP
and UTP.
The P2Y14-R exhibits the most unique agonist selectivity of
the P2Y receptors extant; it was initially identified as an
orphan G protein-coupled receptor that is activated by nucle-
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otide sugars, such as UDP-glucose, UDP-galactose, UDP-N-
acetylglucosamine, and UDP-N-glucuronic acid, rather than
by adenine and/or uridine nucleotides (Chambers et al., 2000;
Freeman et al., 2001). Although the P2Y14-R has been con-
sidered a nucleotide sugar-regulated receptor, we recently
reported that UDP is a competitive antagonist/partial ago-
nist at the human ortholog (Fricks et al., 2008). Moreover,
our experiments with the rat P2Y14-R suggested that UDP is
a potent full agonist at this receptor. These studies revealing
activities of UDP were carried out in COS-7 cells transiently
coexpressing recombinant P2Y14-R with a chimeric G pro-
tein, Gq/i (Coward et al., 1999) that couples Gi-activating
receptors to activation of phospholipase C- isozymes. Thus,
we questioned whether the action of UDP previously ob-
served by measuring inositol lipid hydrolysis was a vagary of
the test system used. To address this issue, agonist activities
were quantified in three different stable cell lines we devel-
oped that allow study of P2Y14-R-dependent inhibition of
adenylyl cyclase activity. These experiments measuring a
natural cell signaling response of the P2Y14-R reveal that not
only is UDP an agonist of the human receptor, but its potency
and apparent efficacy are similar to that of UDP-glucose and
other nucleotide sugars. Thus, the pervasive view that the
P2Y14-R is selectively activated by UDP-glucose and other
nucleotide sugars should be reassessed with the idea that
extracellular UDP is also an important cognate agonist of
this receptor.
Materials and Methods
Cell Lines Stably Expressing P2Y14-R. Human embryonic kid-
ney 293 cells stably expressing the hP2Y14-R (P2Y14-HEK293 cells) and
C6 rat glioma cells stably expressing the hP2Y14-R (P2Y14-C6 cells)
were generated as described previously (Fricks et al., 2009). Chinese
hamster ovary cells stably expressing the hP2Y14-R (P2Y14-CHO cells)
were produced using similar methods. In brief, hP2Y14-R cDNA was
ligated into the retroviral expression vector pLXSN as described previ-
ously (Wolff et al., 2005), and recombinant retrovirus for hP2Y14-R
expression was produced in PA317 cells. CHO cells were incubated with
hP2Y14-R virus and 0.4 mg/ml G418 for 2 weeks to produce hP2Y14-R-
expressing cells.
Cell Culture. HEK293 cells were grown in DMEM supplemented
with 10% fetal bovine serum and 1% G418 (Geneticin) at 37°C in a
5% CO2 environment. C6 rat glioma cells were cultured in DMEM
supplemented with 5% fetal bovine serum and 1% G418 in a 5% CO2
environment. CHO cells were grown in Ham’s F-12 medium supple-
mented with 10% fetal bovine serum and 1% G418 at 37°C in a 5%
CO2 environment. 1321N1 Human astrocytoma cells were grown in
DMEM supplemented with 5% fetal bovine serum in a 5% CO2
environment. HL-60 promyeloleukemia cells were maintained in
RPMI 1640 medium supplemented with 10% fetal bovine serum.
Differentiation of HL-60 cells was achieved by inclusion of 1.3%
DMSO in the culture medium for 5 days.
Cyclic AMP Accumulation. Cells were grown in 24-well plates
and incubated with 1 Ci of [3H]adenine/well in serum-free DMEM
for 2 h before assay. Assays were initiated by the addition of HEPES-
buffered, serum-free DMEM containing 200 M 3-isobutyl-1-meth-
ylxanthine and agonists, and incubation continued for 10 min at
37°C. Incubations were terminated by aspiration of medium and
addition of 500 l of ice-cold 5% trichloroacetic acid. [3H]cAMP was
isolated by sequential Dowex and alumina chromatography and
quantified by liquid scintillation counting as described previously
(Harden et al., 1982).
Inostiol Phosphate Accumulation. P2Y6-R-dependent activa-
tion of phospholipase C was measured by quantifying [3H]inositol
phosphate accumulation in 1321N1 human astrocytoma cells as de-
scribed previously (Besada et al., 2006).
MAP Kinase Activation Assays. Phosphorylation of ERK1/2
was quantified as we have described in detail (Fricks et al., 2009). In
brief, wild-type HEK293 or P2Y14-HEK293 cells were serum-starved
for 18 h before addition of either UDP or UDP-glucose for 15 min at
37°C. Undifferentiated or differentiated HL-60 cells were serum-
starved for 18 h before addition of agonist for 30 min at 37°C. Cell
extracts were subjected to SDS-polyacrylamide gel electrophoresis
on a 12.5% polyacrylamide gel. Proteins were transferred to a nitro-
cellulose membrane, which was sequentially incubated with anti-
body for phospho-ERK1/2, with horseradish peroxidase-conjugated
goat anti-mouse antibody, and with chemiluminescent substrate
(Pierce West Pico system; Thermo Fisher Scientific, Waltham, MA)
and then was exposed to film. Membranes were stripped and re-
probed with a primary antibody against total ERK1/2 to verify equal
loading of lanes.
Data Analysis. EC50 values were determined using Prism soft-
ware (GraphPad, San Diego, CA) and are presented as mean  S.E.
All experiments were repeated at least three times.
Materials. 3-Isobutyl-1-methylxanthine and forskolin were pur-
chased from SigmaAldrich (St. Louis, MO). UDP-glucose, UDP, CDP,
GDP, and ADP were all from FLUKA and were purchased from
SigmaAldrich. High-performance liquid chromatography analysis
of UDP-glucose and all of the nucleotides revealed 95% purity.
Pertussis toxin was purchased from List Biologicals (Campbell,
CA). [3H]Adenine was purchased from American Radiolabeled
Chemicals (St. Louis, MO). G418, serum, and all cell culture
medium were from Invitrogen (Carlsbad, CA). Antibodies for
phosphoERK1/2 and ERK1/2 were purchased from Cell Signaling
Technologies (Danvers, MA).
Results
Agonist-promoted activation of Gi and consequential inhi-
bition of adenylyl cyclase is thought to be a primary signaling
response of the P2Y14-R and other members of the P2Y12-R
subfamily of P2Y receptors. However, most studies of P2Y14-
R-promoted signaling have relied on overexpression of either
G16 or a chimera of Gq (Gq/i) that engineers coupling of
this Gi-coupled receptor to activation of phospholipase C
(Chambers et al., 2000; Freeman et al., 2001; Fricks et al.,
2008). Using C6 rat glioma cells stably expressing the human
P2Y14-R, we recently illustrated that adenylyl cyclase activ-
ity in both intact cells and isolated membranes was inhibited
by UDP-glucose in a concentration- and pertussis toxin-sen-
sitive manner (Fricks et al., 2009). Based on these and sim-
ilar results obtained with hP2Y14-HEK293 cells, we reasoned
that cells displaying P2Y14-R-promoted inhibition of adenylyl
cyclase provide a more physiologically relevant system for
quantification of P2Y14-R-dependent signaling over an engi-
neered signaling system that depends on overexpression of a
G protein that activates phospholipase C. Given our recent
observation of activities of UDP at the P2Y14-R transiently
expressed with an unnatural chimeric G protein, Gq/i, in
COS-7 cells, we believed it important to quantify the relative
actions of UDP and UDP-glucose for promotion of a native
cell signaling response in cell lines stably expressing the
human P2Y14-R.
Whereas UDP-glucose had no effect on cyclic AMP accu-
mulation in wild-type HEK293 cells (Fig. 1A), incubation of
P2Y14-HEK293 cells with this nucleotide sugar resulted in a
concentration-dependent inhibition of forskolin-stimulated
cyclic AMP accumulation (Fig. 1B). Likewise, UDP had no
effect in wild-type HEK293 cells (Fig. 1A) but promoted a
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concentration-dependent decrease in cyclic AMP accumula-
tion in P2Y14-HEK293 cells. The potency (Table 1) and max-
imal effect (Table 2) of UDP for inhibition of forskolin-stim-
ulated cyclic AMP accumulation were very similar to the
potency and maximal effect of UDP-glucose. As was previ-
ously observed with UDP-glucose (Fricks et al., 2009), UDP
had no effect on cyclic AMP accumulation in P2Y14-HEK293
cells in which GPCR-promoted activation of Gi was inhibited
by preincubation of cells with pertussis toxin (Fig. 1C).
The effect of UDP on cyclic AMP accumulation was ob-
served in several different cell lines cloned from hP2Y14-R
virus-infected HEK293 cells (data not shown). Although
these results strongly suggest that UDP is a robust natural
agonist of this receptor, we concluded it prudent to test
possible agonist action of UDP at P2Y14-R stably expressed
in other cell backgrounds. Therefore, activity of UDP was
assessed in a stable cell line (P2Y14-C6 cells) that we recently
developed (Fricks et al., 2009), as well as in a third stable cell
line (P2Y14-CHO cells) that was generated as described un-
der Materials and Methods. Again, neither UDP-glucose nor
UDP affected basal or forskolin-stimulated cyclic AMP accu-
mulation in wild-type C6 (Fig. 2A) or CHO (data not shown)
cells. In contrast, concentration-dependent effects of both
UDP-glucose and UDP were observed in P2Y14-C6 (Fig. 2B)
and P2Y14-CHO (Fig. 2C) cells. The maximal inhibition of
forskolin-stimulated cyclic AMP accumulation observed with
UDP was similar to that observed with UDP-glucose in these
two cell lines (Table 2), and the EC50 values of UDP and
UDP-glucose also were similar (Table 1). The effect of both
UDP-glucose and UDP on cyclic AMP accumulation was
blocked by preincubation of P2Y14-C6 cells (Fig. 3A) or
P2Y14-CHO cells (Fig. 3B) with pertussis toxin.
TABLE 1
Comparative potencies of UDP-glucose and UDP in cell lines stably
expressing the human P2Y14-R. Concentration effect curves for UDP-
glucose- and UDP-promoted inhibition of forskolin-stimulated cyclic
AMP accumulation were generated in P2Y14-HEK293, P2Y14-C6, and
P2Y14-CHO cells as described under Materials and Methods. Assays
were carried out in triplicate, and EC50 values were determined from
individual experiments by applying the Prism software package. The
EC50 values are presented as mean  S.E.M. averaged from 6
experiments each with C6 and CHO cells and from 21 experiments
with HEK293 cells.
EC50
Cell Line UDP-Glucose UDP
nM
P2Y14-HEK293 cells 323  84 74  18
P2Y14-CHO cells 132  76 33  20


















































































































Fig. 1. UDP-glucose and UDP promote pertussis toxin-sensitive inhibi-
tion of cyclic AMP accumulation in P2Y14-HEK293 cells. A, the capacity
of 100 M UDP or 100 M UDP-glucose (UDPG) to inhibit forskolin (Fsk;
30 M)-stimulated cyclic AMP accumulation was quantified in wild-type
HEK293 cells as described under Materials and Methods. The data are
mean  S.E.M. from triplicate determinations and are representative of
three separate experiments. B, concentration-dependent inhibition of
forskolin-stimulated cyclic AMP accumulation by UDP-glucose and UDP.
P2Y14-HEK293 cells were incubated with 30 M forskolin alone or 30 M
forskolin plus the indicated concentrations of UDP-glucose (f) or UDP
(). The data are presented as mean  S.E.M. of triplicate determina-
tions and are representative of data from six experiments. C, blockade of
the P2Y14-R-dependent effects of UDP-glucose and UDP by pertussis
toxin (PT). P2Y14-HEK293 cells were incubated overnight with vehicle or
100 ng/ml pertussis toxin, and cyclic AMP accumulation was subse-
quently measured in the presence of 30 M forskolin alone or with 30 M
forskolin plus 10 M UDP-glucose or 10 M UDP. The data are presented
as mean  S.E.M. of results from three separate experiments.
TABLE 2
The maximal percentage inhibition of forskolin-stimulated cAMP





Cell Line UDP-Glucose UDP
%
P2Y14-HEK293 cells 60  6 58  2
P2Y14-CHO cells 70  10 68  9
P2Y14-C6 cells 86  3 91  1
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The agonist activity of other naturally occurring nucleoside
diphosphates was tested in P2Y14-HEK293 cells. Both CDP
and GDP exhibited agonist activities, although the potencies
observed were more than 100-fold less than that observed
with UDP (Fig. 4). The effect of ADP, which is the cognate
agonist of the P2Y1, P2Y12, and P2Y13 receptors, was also
examined. Incubation of P2Y14-HEK293 cells with low
micromolar concentrations of ADP resulted in a reproduc-
ible increase in cyclic AMP accumulation, and high micro-
molar concentrations of ADP reduced cyclic AMP accumula-
tion to levels similar to that observed with forskolin alone.
The stimulatory effect of ADP also was observed in wild-type
HEK293 cells, but the small inhibitory effect observed at
high concentrations of ADP was not (data not shown). Thus,
ADP exhibited only P2Y14-R-dependent activity at very high
concentrations relative to those necessary for agonist effects
of UDP. A potential explanation of the stimulatory effect of
ADP in both wild-type and P2Y14-HEK293 cells is that ec-
Fig. 2. P2Y14-R-dependent activities of UDP-glucose and UDP in
P2Y14-C6 and P2Y14-CHO cells. A, the capacity of 100 M UDP or 100 M
UDP-glucose (UDPG) to inhibit forskolin (30 M)-stimulated cyclic AMP
accumulation was quantified in wild-type C6 rat glioma cells as described
under Materials and Methods. The data are mean  S.E.M. from tripli-
cate determinations and are representative of results from three separate
experiments. B, concentration-dependent inhibition of forskolin-stimu-
lated cyclic AMP accumulation by UDP-glucose and UDP in P2Y14-C6
cells. P2Y14-C6 cells were incubated in the presence of 30 M forskolin
alone or with 30 M forskolin plus the indicated concentrations of UDP-
glucose (f) or UDP (). The data are presented as mean  S.E.M. of
triplicate determinations and are representative of data from six separate
experiments. C, concentration-dependent inhibition of forskolin-stimu-
lated cyclic AMP accumulation by UDP-glucose and UDP in P2Y14-CHO
cells. P2Y14-CHO cells were incubated in the presence of 30 M forskolin
alone or with 30 M forskolin plus the indicated concentrations of UDP-
glucose (f) or UDP (). The data are presented as mean  S.E.M. of
triplicate determinations and are representative of data from six separate
experiments.
Fig. 3. Pertussis toxin sensitivity of the effects of UDP-glucose and UDP
in P2Y14-C6 cells and P2Y14-CHO cells. A, blockade of the P2Y14-R-
dependent effects of UDP-glucose and UDP by pertussis toxin in
P2Y14-C6 cells. P2Y14-C6 cells were incubated overnight with vehicle or
100 ng/ml pertussis toxin, and cyclic AMP accumulation was subse-
quently measured in the presence of 30 M forskolin alone or with 30
M forskolin plus 10 M UDP-glucose or 10 M UDP. The data are
presented as mean  S.E.M. of results from three separate experi-
ments. B, blockade of the P2Y14-R-dependent effects of UDP-glucose
and UDP by pertussis toxin in P2Y14-CHO cells. P2Y14-CHO cells were
incubated overnight with vehicle or 100 ng/ml pertussis toxin, and
cyclic AMP accumulation was subsequently measured in the presence
of 30 M forskolin alone or with 30 M forskolin plus 10 M UDP-
glucose or 10 M UDP. The data are presented as mean  S.E.M. of
results from three separate experiments.
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toenzymes convert ADP to adenosine, which in turn activates
an endogenous A2B adenosine receptor known to be present
on HEK293 cells (Cooper et al., 1997; Mundell et al., 1999).
Potential agonist activities of the UDP analogs, UDPS
(Malmsjö et al., 2000) and 2-thio-UDP (Besada et al., 2006)
also were examined in P2Y14-HEK293 cells. As is illustrated
in Fig. 5, both UDPS (EC50  26  11 nM, n  3) and
2-thio-UDP (EC50  2  1 nM, n  3) were potent agonists at
the hP2Y14-R.
We recently reported that stable expression of the human
P2Y14 receptor in HEK293 cells confers a robust MAP kinase
signaling response to UDP-glucose (Fricks et al., 2009).
Therefore, the capacity of UDP to promote P2Y14-R-depen-
dent phosphorylation of ERK1/2 also was examined. As illus-
trated in Fig. 6, 10 M UDP had no effect on the MAP kinase
response in wild-type HEK293 cells but promoted marked
ERK1/2 phosphorylation in P2Y14-HEK293 cells. Thus, as
was observed in measurements of cyclic AMP accumulation,
quantification of MAP kinase signaling also reveals that
UDP and UDP-glucose exhibit similar agonist activities at
the P2Y14 receptor.
The results presented thus far with the human P2Y14-R
stably expressed in three different cell types strongly suggest
that UDP is a potent agonist at this receptor. We also re-
cently discovered that the P2Y14-R is natively expressed in
HL-60 promyeloleukemia cells (Fricks et al., 2009). Whereas
neither P2Y14-R mRNA nor a MAP kinase signaling response
to UDP-glucose was detectable in wild-type HL-60 cells, dif-
ferentiation of these cells by addition of DMSO to the growth
medium resulted in expression of P2Y14-R mRNA as well as
phosphorylation of ERK1/2 in response to UDP-glucose.
Thus, HL-60 cells also were studied to examine whether UDP
activates signaling responses downstream of a natively ex-
pressed P2Y14-R. ERK1/2 phosphorylation was observed in
response to UDP in differentiated HL60 cells (data not
shown), but further experiments revealed that a robust re-
sponse to UDP also was seen in wild-type HL60 cells in the
absence of P2Y14-R expression (Fig. 7A). Reverse transcrip-
tion-polymerase chain reaction analyses revealed that the
response observed to UDP in wild-type HL60 cells is probably
due to the presence of a UDP-activated P2Y6-R, because
mRNA for this receptor is prominently expressed in both
wild-type and differentiated HL60 cells (data not shown).
Although quantification of inhibition of cyclic AMP accumu-
lation potentially might allow resolution of the effects of UDP
on the Gi-coupled P2Y14-R versus Gq-coupled P2Y6-R in these
cells, we have been unable to observe inhibition of adenylyl
cyclase in response to UDP-glucose or formyl-Met-Leu-Phe,
which activates a Gi-linked receptor for chemotactic peptides
in HL-60 cells (Fricks et al., 2009).
In the absence of availability of another cell line that
Fig. 4. Agonist activities of nucleoside diphosphate molecules in P2Y14-
HEK293 cells. P2Y14-HEK293 cells were incubated in the presence of 30
M forskolin alone or with 30 M forskolin plus the indicated concentra-
tions of UDP (), CDP (ƒ), GDP (}), or ADP (). The data are presented
as mean  S.E.M. of results pooled from three separate experiments.
Fig. 5. Agonist activities of 2-thio-UDP and UDPS in P2Y14-HEK293
cells. P2Y14-HEK293 cells were incubated in the absence (E) or presence
of 30 M forskolin alone or with 30 M forskolin plus the indicated
concentrations of 2-thio-UDP () or UDPS (‚). The data are presented
as mean  S.E.M. of triplicate determinations and are representative of
data from three separate experiments.
Fig. 6. P2Y14-R-dependent activation of MAP kinase signaling by UDP.
Empty vector or P2Y14-HEK293 cells were serum-starved for 18 h before
incubation with vehicle, 10 M UDP, or 10 M UDP-glucose for 15 min.
Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis,
the samples transferred to nitrocellulose membranes, and the mem-
branes probed with antibodies for phospho-ERK1/2 and total ERK1/2 as
described under Materials and Methods. The results shown are represen-
tative of data from three individual experiments.
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natively expresses the P2Y14-R, we considered a pharmaco-
logical approach to show that the P2Y14-R natively expressed
on differentiated HL-60 cells responds to agonists in addition
to nucleotide sugars. As illustrated above (Fig. 5), two UDP
analogs activated the P2Y14-R stably expressed in HEK293
cells. Because these two molecules also are potent activators
of the P2Y6-R (data not shown), they are not useful for
selectively activating the P2Y14-R of HL-60 cells. However,
our recent chemical syntheses (A. Das, H. Ko, M. O. Barrett,
L. B. Burianek, T. K. Harden, and K. A. Jacobson, submitted)
have identified analogs of UDP that activate the P2Y14-R
without activating the P2Y6-R, and the relative activities of
two of these, MRS2802 and MRS2907, at the P2Y14-R versus
P2Y6-R are illustrated in Fig. 7. MRS2802 inhibited forsko-
lin-stimulated cyclic AMP accumulation in P2Y14-HEK293
cells with an EC50 of approximately 50 nM (Fig. 7B, left),
whereas little inositol phosphate response to this molecule
was observed at concentrations up to 10 M in 1321N1 hu-
man astrocytoma cells stably expressing the human P2Y6-R
(Fig. 7B, right). MRS2907 also selectively activated the
P2Y14-R over the P2Y6-R (Fig. 7C). Given the P2Y14-R selec-
tivity of these two UDP analogs, we examined their capacity
to stimulate ERK1/2 phosphorylation in wild-type and differ-
entiated HL-60 cells. Neither MRS2802 nor MRS2907 pro-
moted ERK1/2 phosphorylation in wild-type HL-60 cells (Fig.
7D), but as was the case with UDP-glucose, a MAP kinase
signaling response to both analogs was observed after induc-
tion of expression of the P2Y14-R by differentiation of these
cells by treatment with DMSO. These results are consistent
with the idea that UDP analogs, and by deduction UDP itself,
are potent agonists of the P2Y14-R in a native environment.
Discussion
The results of this study illustrate that UDP is a cognate
agonist of the human P2Y14-R. Agonist activity of UDP was
observed in three different cell backgrounds in which the
capacity of the human P2Y14-R to promote inhibition of for-
skolin-stimulated adenylyl cyclase activity was quantified.
Given that the potency of UDP is similar to that of UDP-
glucose and other nucleotide sugars for activation, we con-
clude that UDP is a physiologically important agonist of the
human P2Y14-R.
Previous studies of P2Y14-R have focused almost entirely
on the activity of uridine nucleotide sugars. Chambers and
colleagues (Chambers et al., 2000; Freeman et al., 2001)
first reported that the orphan GPCR, KIAA0001, subse-
quently named the P2Y14-R, is activated by UDP-glucose,
UDP-galactose, UDP-glucuronic acid, and UDP-N-acetylglu-
cosamine. In contrast, a broad range of other nucleotide
sugars and nucleotides, including UDP, were reported to be
inactive at this receptor. These initial pharmacological stud-
ies used three different systems to quantify agonist activities.
A yeast transcription reporter assay system was applied that
tested human P2Y14-R-dependent activity during overnight
incubation with potential agonists. The human P2Y14-R also
was transiently expressed in HEK293 cells with G16, a
heterotrimeric G protein that promiscuously couples to most
agonist-activated GPCR and confers agonist-dependent acti-
vation of phospholipase C and mobilization of Ca2 to these
receptors. Finally, membranes were prepared from HEK293
cells that stably expressed the human P2Y14-R, and UDP-
glucose-promoted binding of [35S]GTPS to endogenous G
proteins was quantified.
It is unclear why agonist activity of UDP was not observed
Fig. 7. Activation of a P2Y14-R-dependent MAP kinase signaling re-
sponse in differentiated human HL-60 promyeloleukemia cells. A, phos-
phorylation of ERK1/2 (phospho-ERK1/2) was analyzed in wild-type
HL-60 cells after incubation for the indicated times with 10 M UDP or
10 M UDP-glucose (UDPG) as described under Materials and Methods.
Levels of total ERK1/2 also are presented. B, concentration effect curves
for MRS2802 for activation of P2Y14-R in P2Y14-HEK293 cells and acti-
vation of P2Y6-R in 1321N1 human astrocytoma cells stably expressing
the human P2Y6-R were generated as described under Materials and
Methods. C, concentration effect curves for MRS2907 for activation of
P2Y14-R in P2Y14-HEK293 cells and activation of P2Y6-R in 1321N1
human astrocytoma cells stably expressing the human P2Y6-R were
generated as described under Materials and Methods. D, phosphorylation
of ERK1/2 (phospho-ERK1/2) was quantified in undifferentiated
(DMSO) or differentiated (DMSO) HL-60 cells after incubation for 30
min with 10 M UDP-glucose (UDPG), 1 M MRS2907, or 10 M
MRS2802 as described under Materials and Methods. Levels of total
ERK1/2 also are presented.
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in early studies of the P2Y14-R. The yeast transcription assay
and assays that take advantage of promiscuous coupling of
GPCR to G16 provide robust assessments of GPCR activity.
However, because neither of these systems measure coupling
to the cognate heterotrimeric G protein known to mediate
P2Y14-R-promoted signaling responses, it is possible that a
receptor conformation is favored in these test systems that
does not fully reflect the ligand binding selectivities and
agonist activities of the physiological receptor coupling to its
cognate heterotrimeric G protein and signaling pathway. On
the other hand, these early studies included assays of ago-
nist-promoted binding of [35S]GTPS to endogenous G pro-
teins in membranes from P2Y14-R-expressing HEK293 cells,
and UDP-glucose promoted increases in [35S]GTPS binding
that were 40% greater than basal. This activity apparently
reflected agonist-induced coupling to a G-subunit(s) of the
Gi family because it was inhibited by pertussis toxin. It is
noteworthy that concentration effect curves for four different
nucleotides, including UDP, were generated with this test sys-
tem, and that in contradistinction to the stimulatory effect of
UDP-glucose, all four nucleotides inhibited [35S]GTPS binding
in a concentration dependent manner. However, this effect
was not dependent on expression of the P2Y14-R, was not
blocked by pertussis toxin, and therefore apparently repre-
sented a nonspecific effect on binding of [35S]GTPS to un-
specified proteins. Given the magnitude of this inhibitory
effect of nucleotides and the relatively small magnitude of
P2Y14-R-dependent UDP-glucose-promoted increases in
[35S]GTPS binding, the sensitivity of this test system ap-
parently was not sufficient to reveal an agonist action of UDP
at the P2Y14-R.
We recently reported that UDP exhibits competitive antag-
onist/partial agonist activity in measurements of [3H]inositol
phosphate accumulation in COS-7 cells transiently coex-
pressing the hP2Y14-R with a chimeric G protein Gq/i that
confers a phospholipase C/Ca2 signaling response to Gi-
activating receptors (Fricks et al., 2008). It is noteworthy
that UDP seemed to be a full agonist in parallel studies with
the rat P2Y14-R. Moreover, our unpublished studies examin-
ing activities of the human P2Y14-R cotransfected with Gq/i
in COS-7 cells show that an antagonist/partial agonist action
of UDP is observed only at very low levels of receptor expres-
sion. With higher receptor expression, UDP exhibits maximal
agonist effects that are similar to those of UDP-glucose. As
we speculated above concerning studies with G16, a confor-
mation of the P2Y14-R may be favored when this receptor is
coupled to Gq/i, which results in ligand binding selectivities
and agonist activities that are not altogether consistent with
activities of the receptor obtained when coupled to its cognate
heterotrimeric G protein. The idea that relative receptor
activation by ligands is influenced by both the levels of sig-
naling proteins and the particular G protein signaling system
studied is supported by previous studies of a variety of G
protein-coupled receptors (Cordeaux et al., 2004; Kenakin,
2007; Urban et al., 2007). The work of Ault and Broach using
directed evolution in yeast first suggested an interaction of
UDP with the hP2Y14-R, and their studies with various mu-
tants of the human P2Y14-R also suggested a range of activ-
ities of this diphosphate relative to activities observed with
UDP-glucose (Ault and Broach, 2006).
Our data with P2Y14-HEK293, P2Y14-C6, and P2Y14-CHO
cells all reveal potent agonist activity of UDP. The maximal
inhibitory effect on adenylyl cyclase observed with UDP was
the same as that of UDP-glucose, which is consistent with the
idea that UDP is a full agonist at the hP2Y14-R. However, we
cannot unequivocally rule out the possibility that under lim-
iting receptor concentrations, UDP would prove to be a par-
tial agonist. A radioligand is not available for quantification
of P2Y14-R; consequently, the density of receptors cannot be
determined in these cells with current technology. Nonethe-
less, viral expression of GPCR predictably results in receptor
levels that do not substantively exceed that of native recep-
tors. We also have isolated a series of clonal P2Y14-HEK293
cell lines that exhibit varying amounts of expression of
P2Y14-R quantified by surface epitope-tagging. UDP and
UDP-glucose are similarly efficacious in each of these cell
lines tested. Finally, the presence of an endogenous UDP-
activated P2Y6-R on HL-60 promyeloleukemia cells pre-
cludes straightforward testing of UDP as a P2Y14-R agonist
on these cells. However, the fact that P2Y14-R-selective an-
alogs of UDP promoted phosphorylation of ERK1/2 in differ-
entiated, but not in undifferentiated, HL-60 cells also is
consistent with the conclusion that UDP is an agonist of the
P2Y14-R.
Although the P2Y14-R has been thought to be solely regu-
lated by UDP sugars, we conclude that this signaling protein
is also significantly activated by UDP. Lazarowski and col-
leagues have hypothesized that P2Y14-R-activating nucleo-
tide sugars arise from cellular protein secretory pathways
(Lazarowski et al., 2003). Although we have illustrated that
mechanical stimulation promotes release of UTP into the
extracellular medium from a broad range of cells (Laz-
arowski et al., 1997; Lazarowski and Harden, 1999), the
source of extracellular UDP remains unclear. One idea is
that ecto-nucleotide triphosphate-diphosphohydrolase 2,
which converts nucleoside triphosphates to nucleoside
diphosphates (Zimmermann, 2000), converts UTP to UDP at
the cell surface. For example, the pharmacological effects of
ATP at the ADP-activated P2Y1 receptor are markedly aug-
mented by expression of ectoNTPDase2 (Alvarado-Castillo
et al., 2005). Alternatively, UDP could be released from a
secretory pathway, as suggested by Tatur et al. (2008). Be-
cause UDP and UDP-sugars participate in glycosylation re-
actions in the Golgi lumen, one speculation is that both
species are released concomitantly during vesicle exocytosis.
Perhaps a common source of the two agonists in part explains
the evolution of a receptor that is dually activated by UDP
and UDP sugars. The P2Y14-R has been implicated in regu-
lation of immune responses (Fumagalli et al., 2003; Skelton
et al., 2003; Müller et al., 2005; Scrivens and Dickenson,
2005; Scrivens and Dickenson, 2006), and it will be important
to establish that both UDP-glucose and UDP play important
and possibly differing roles in this function.
An intriguing aspect of the discovery that UDP is an ago-
nist of the P2Y14-R is that the P2Y14-R and the UDP-acti-
vated P2Y6-R have overlapping cellular distributions (Burn-
stock and Knight, 2004). One of the best understood
physiological responses mediated by P2Y-R is the ADP-pro-
moted aggregation of platelets, which requires coordinated
activation of both the Gi-coupled P2Y12 receptor and the
Gq-coupled P2Y1 receptor (Gachet, 2006). We hypothesize
that certain physiological responses to extracellular UDP
also require coordinated activation of the Gq-activating
P2Y6-R and the Gi-activating P2Y14-R. A current goal of our
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research is to develop receptor selective ligands that allow
pharmacological resolution of the activities of these two re-
ceptors in native tissues.
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